Epigenetic therapy of hematological malignancies: Where are we now?

Therapeutic Advances in Hematology

Volumn 4, Issue 2, 2013, Pages 81-91

  Popovic, Relja ^a   Shah, Mrinal Y ^a   Licht, Jonathan D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

epigenetics; EZH2; methylation; MLL

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 HYDROXYMETHYLCYTOSINE; 5 [4 (2 DIETHYLAMINOETHYLAMINO) 3 NITROPHENYL] 1,4 DIPHENYL 1,2,4 TRIAZOLIUM 3 THIOLATE; AZACITIDINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; HISTONE DEACETYLASE INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; TRANSCRIPTION FACTOR EZH2;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CELL; CANCER GENE THERAPY; CANCER GROWTH; CELL DIFFERENTIATION; CELL FUNCTION; CHRONIC MYELOMONOCYTIC LEUKEMIA; DNA METHYLATION; DRUG EFFICACY; ENZYME ACTIVITY; EPIGENETIC REPRESSION; EPIGENETIC THERAPY; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENOME; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HISTONE METHYLATION; HOX GENE; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84993729302     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712466864     Document Type: Review

References (85)

1. Abdel-Wahab O. Mullally A. Hedvat C. Garcia-Manero G. Patel J. Wadleigh M. et al. (2009) Genetic characterization of TET1, TE2, and TET 3 alterations in myeloid malignancies. Blood 114: 144–147.
2. Abdel-Wahab O. Pardanani A. Patel J. Wadleigh M. Lasho T. Heguy A. et al. (2011) Concomitant analysis of EZH 2 and ASX 1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25: 1200–1202.
3. Agger K. Cloos P.A. Christensen J. Pasini D. Rose S. Rappsilber J. et al. (2007) UTX and JMJD 3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449: 731–734.
4. Albert M. Helin K. (2010) Histone methyltransferases in cancer. Semin Cell Dev Biol 21: 209–220.
5. Benedikt A. Baltruschat S. Scholz B. Bursen A. Arrey T.N. Meyer B. et al. (2011) The leukemogenic AF4-MLL fusion protein causes P-TEFB kinase activation and altered epigenetic signatures. Leukemia 25: 135–144.
6. Bernstein B.E. Mikkelsen T.S. Xie X. Kamal M. Huebert D.J. Cuff J. et al. (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315–326.
7. Bernt K.M. Zhu N. Sinha A.U. Vempati S. Faber J. Krivtsov A.V. et al. (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66–78.
8. Bestor T.H. (2000) The DNA methyltransferases of mammals. Hum Mol Genet 9: 2395–2402.
9. Bitoun E. Oliver P.L. Davies K.E. (2007) The mixed-lineage leukemia fusion partner AF 4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 16: 92–106.
10. Bracken A.P. Dietrich N. Pasini D. Hansen K.H. Helin K. (2006) Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20: 1123–1136.
11. Broske A.M. Vockentanz L. Kharazi S. Huska M.R. Mancini E. Scheller M. et al. (2009) DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 41: 1207–1215.
12. Brueckner B. Garcia Boy R. Siedlecki P. Musch T. Kliem H.C. Zielenkiewicz P. et al. (2005) Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 65: 6305–6311.
13. Cameron E.E. Bachman K.E. Myohanen S. Herman J.G. Baylin S.B. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103–107.
14. Challen G.A. Sun D. Jeong M. Luo M. Jelinek J. Berg J.S. et al. (2012) DNMT3A is essential for hematopoietic stem cell differentiation. Nat Genet 44: 23–31.
15. Chang M.J. Wu H. Achille N.J. Reisenauer M.R. Chou C.W. Zeleznik-Le N.J. et al. (2010) Histone H 3 lysine 79 methyltransferase DOT 1 is required for immortalization by MLL oncogenes. Cancer Res 70: 10234–10242.
16. Daigle S.R. Olhava E.J. Therkelsen C.A. Majer C.R. Sneeringer C.J. Song J. et al. (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20: 53–65.
17. Dawson M.A. Prinjha R.K. Dittmann A. Giotopoulos G. Bantscheff M. Chan W.I. et al. (2011) Inhibition of bet recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 529–533.
18. Delhommeau F. Dupont S. Della Valle V. James C. Trannoy S. Masse A. et al. (2009) Mutation in TET 2 in Mmyeloid cancers. N Engl J Med 360: 2289–2301.
19. Delmore J.E. Issa G.C. Lemieux M.E. Rahl P.B. Shi J. Jacobs H.M. et al. (2011) Bet bromodomain inhibition as a therapeutic strategy to target c-MYC. Cell 146: 904–917.
20. Dimicoli S. Jabbour E. Borthakur G. Kadia T. Estrov Z. Yang H. et al. (2012) Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87: 127–129.
21. Ernst T. Chase A.J. Score J. Hidalgo-Curtis C.E. Bryant C. Jones A.V. et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH 2 in myeloid disorders. Nat Genet 42: 722–726.
22. Fandy T.E. Herman J.G. Kerns P. Jiemjit A. Sugar E.A. Choi S.H. et al. (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114: 2764–2773.
23. Fenaux P. Mufti G.J. Hellstrom-Lindberg E. Santini V. Finelli C. Giagounidis A. et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223–232.
24. Figueroa M.E. Abdel-Wahab O. Lu C. Ward P.S. Patel J. Shih A. et al. (2010) Leukemic IDH 1 and IDH 2 mutations result in a hypermethylation phenotype, disrupt TET 2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553–567.
25. Figueroa M.E. Lugthart S. Li Y. Erpelinck-Verschueren C. Deng X. Christos P.J. et al. (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17: 13–27.
26. Figueroa M.E. Skrabanek L. Li Y. Jiemjit A. Fandy T.E. Paietta E. et al. (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114: 3448–3458.
27. Garcia-Manero G. Gore S.D. Cogle C. Ward R. Shi T. Macbeth K.J. et al. (2011) Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29: 2521–2527.
28. Giles F. Fischer T. Cortes J. Garcia-Manero G. Beck J. Ravandi F. et al. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12: 4628–4635.
29. Gore S.D. (2011) New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2011: 550–555.
30. Gore S.D. Baylin S. Sugar E. Carraway H. Miller C.B. Carducci M. et al. (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361–6369.
31. Green A. Beer P. (2010) Somatic mutations of IDH 1 and IDH 2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362: 369–370.
32. Grembecka J. He S. Shi A. Purohit T. Muntean A.G. Sorenson R.J. et al. (2012) Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 8 : 277–284.
33. Guo J.U. Su Y. Zhong C. Ming G.L. Song H. (2011) Hydroxylation of 5-methylcytosine by TET 1 promotes active DNA demethylation in the adult brain. Cell 145: 423–434.
34. Halby L. Champion C. Senamaud-Beaufort C. Ajjan S. Drujon T. Rajavelu A. et al. (2012) Rapid synthesis of new DNMT inhibitors derivatives of procainamide. Chembiochem 13: 157–165.
35. Hubner M.R. Spector D.L. (2011) Role of H3k27 demethylases JMJD 3 and UTX in transcriptional regulation. Cold Spring Harb Symp Quant Biol:
36. Hudlebusch H.R. Santoni-Rugiu E. Simon R. Ralfkiaer E. Rossing H.H. Johansen J.V. et al. (2011) The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res 17: 2919–2933.
37. Jo S.Y. Granowicz E.M. Maillard I. Thomas D. Hess J.L. (2011) Requirement for DOT1L in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 117: 4759–4768.
38. Kihslinger J.E. Godley L.A. (2007) The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma 48: 1676–1695.
39. Kleer C.G. Cao Q. Varambally S. Shen R. Ota I. Tomlins S.A. et al. (2003) EZH 2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606–11611.
40. Knutson S.K. Wigle T.J. Warholic N.M. Sneeringer C.J. Allain C.J. Klaus C.R. et al. (2012) A selective inhibitor of EZH 2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8: 890–896.
41. Ko M. Huang Y. Jankowska A.M. Pape U.J. Tahiliani M. Bandukwala H.S. et al. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468: 839–843.
42. Kroeze L.I. Nikoloski G. Da Silva-Coelho P. van Hoogen P. Stevens-Linders E. Kuiper R.P. et al. (2012) Genetic defects in PRC 2 components other than EZH 2 are not common in myeloid malignancies. Blood 119: 1318–1319.
43. Kuck D. Singh N. Lyko F. Medina-Franco J.L. (2010) Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg Med Chem 18: 822–829.
44. Langemeijer S.M. Kuiper R.P. Berends M. Knops R. Aslanyan M.G. Massop M. et al. (2009) Acquired mutations in TET 2 are common in myelodysplastic syndromes. Nat Genet 41: 838–842.
45. Ley T.J. Ding L. Walter M.J. Mclellan M.D. Lamprecht T. Larson D.E. et al. (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424–2433.
46. Li Y. Trojer P. Xu C.F. Cheung P. Kuo A. Drury W.J. et al. (2009) The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem 284: 34283–34295.
47. Lin C. Smith E.R. Takahashi H. Lai K.C. Martin-Brown S. Florens L. et al. (2010) AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 37: 429–437.
48. Lorsbach R.B. Moore J. Mathew S. Raimondi S.C. Mukatira S.T. Downing J.R. (2003) TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;Q23). Leukemia 17: 637–641.
49. Mann B.S. Johnson J.R. Cohen M.H. Justice R. Pazdur R. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247–1252.
50. Mardis E.R. Ding L. Dooling D.J. Larson D.E. Mclellan M.D. Chen K. et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058–1066.
51. Martinez-Garcia E. Popovic R. Min D.J. Sweet S.M. Thomas P.M. Zamdborg L. et al. (2011) The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma Ccells. Blood 117: 211–220.
52. McCabe M.T. Ott H.M. Ganji G. Korenchuk S. Thompson C. van aller G.S. et al. (2012) EZH 2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature.
53. Miranda T.B. Cortez C.C. Yoo C.B. Liang G. Abe M. Kelly T.K. et al. (2009) DZNeP is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579–1588.
54. Moran-Crusio K. Reavie L. Shih A. Abdel-Wahab O. Ndiaye-Lobry D. Lobry C. et al. (2011) TET 2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20: 11–24.
55. Morey L. Helin K. (2010) Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 35: 323–332.
56. Morin R.D. Johnson N.A. Severson T.M. Mungall A.J. An J. Goya R. et al. (2010) Somatic mutations altering EZH 2 (TYR641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181–185.
57. Nakamura T. Mori T. Tada S. Krajewski W. Rozovskaia T. Wassell R. et al. (2002) ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 10: 1119–1128.
58. Nikoloski G. Langemeijer S.M. Kuiper R.P. Knops R. Massop M. Tonnissen E.R. et al. (2010) Somatic mutations of the histone methyltransferase gene EZH 2 in myelodysplastic syndromes. Nat Genet 42: 665–667.
59. Ono R. Taki T. Taketani T. Taniwaki M. Kobayashi H. Hayashi Y. (2002) LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;Q23). Cancer Res 62: 4075–4080.
60. Parsons D.W. Jones S. Zhang X. Lin J.C. Leary R.J. Angenendt P. et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
61. Popovic R. Zeleznik-Le N.J. (2005) MLL: how complex does it get? J Cell Biochem 95: 234–242.
62. Quivoron C. Couronne L. Della Valle V. Lopez C.K. Plo I. Wagner-Ballon O. et al. (2011) TET 2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20: 25–38.
63. Silverman L.R. Demakos E.P. Peterson B.L. Kornblith A.B. Holland J.C. Odchimar-Reissig R. et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429–2440.
64. Sneeringer C.J. Scott M.P. Kuntz K.W. Knutson S.K. Pollock R.M. Richon V.M. et al. (2010) Coordinated activities of wild-type plus mutant EZH 2 drive tumor-associated hypertrimethylation of lysine 27 on histone H 3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 107: 20980–20985.
65. Song J. Rechkoblit O. Bestor T.H. Patel D.J. (2011) Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 331: 1036–1040.
66. Tadokoro Y. Ema H. Okano M. Li E. Nakauchi H. (2007) de novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med 204: 715–722.
67. Tahiliani M. Koh K.P. Shen Y. Pastor W.A. Bandukwala H. Brudno Y. et al. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930–935.
68. Tan J. Yang X. Zhuang L. Jiang X. Chen W. Lee P.L. et al. (2007) Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050–1063.
69. Trowbridge J.J. Snow J.W. Kim J. Orkin S.H. (2009) DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 5: 442–449.
70. van Haaften G. Dalgliesh G.L. Davies H. Chen L. Bignell G. Greenman C. et al. (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521–523.
71. Velichutina I. Shaknovich R. Geng H. Johnson N.A. Gascoyne R.D. Melnick A.M. et al. (2010) EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116: 5247–5255.
72. Vire E. Brenner C. Deplus R. Blanchon L. Fraga M. Didelot C. et al. (2006) The polycomb group protein EZH 2 directly controls DNA methylation. Nature 439: 871–874.
73. Walter M.J. Ding L. Shen D. Shao J. Grillot M. Mclellan M. et al. (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25: 1153–1158.
74. Ward P.S. Patel J. Wise D.R. Abdel-Wahab O. Bennett B.D. Coller H.A. et al. (2010) The common feature of leukemia-associated IDH 1 and IDH 2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225–234.
75. Xu W. Yang H. Liu Y. Yang Y. Wang P. Kim S.H. et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17–30.
76. Yamashita Y. Yuan J. Suetake I. Suzuki H. Ishikawa Y. Choi Y.L. et al. (2010) Array-based genomic resequencing of human leukemia. Oncogene 29: 3723–3731.
77. Yan H. Parsons D.W. Jin G. Mclendon R. Rasheed B.A. Yuan W. et al. (2009) IDH 1 and IDH 2 mutations in gliomas. N Engl J Med 360: 765–773.
78. Yan X.-J. Xu J. Gu Z.-H. Pan C.-M. Gang Lu G. Shen Y. et al. (2011) Exome sequencing reveals frequent mutations of DNA methyltransferase gene DNMT3A with significant clinical relevance in acute monocytic leukemia. Nat Gen 43: 309–315.
79. Yang Z. Yik J.H. Chen R. He N. Jang M.K. Ozato K. et al. (2005) Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein BRD4. Mol Cell 19: 535–545.
80. Yap D.B. Chu J. Berg T. Schapira M. Cheng S.W. Moradian A. et al. (2011) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC 2 catalytic activity, to increase H3K27 trimethylation. Blood 117: 2451–2459.
81. Yokoyama A. Somervaille T.C. Smith K.S. Rozenblatt-Rosen O. Meyerson M. Cleary M.L. (2005) The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123: 207–218.
82. Yoo J. Kim J.H. Robertson K.D. Medina-Franco J.L. (2012) Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNM 1 inhibitor. Adv Protein Chem Struct Biol 87: 219–247.
83. Zhang J. Ding L. Holmfeldt L. Wu G. Heatley S.L. Payne-Turner D. et al. (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481: 157–163.
84. Ziemba A. Hayes E. Freeman B.B. Ye T. Pizzorno G. (2011) Development of an oral form of azacytidine: 2′3′5′triacetyl-5-azacytidine. Chemother Res Pract 2011: 965826.
85. Zuber J. Shi J. Wang E. Rappaport A.R. Herrmann H. Sison E.A. et al. (2011) RNAi screen identifies BRD 4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524–528.